ANZCTR search results

Approximately 750 subjects, presenting with flu-like symptoms, will be prospectively enrolled and samples (nasal swab samples) will be collected from consecutive patients. All subjects will be assigned a unique subject identification (ID) number in sequential order as they are enrolled into the study. Each site will collect two nasal swabs from each subject. Clearview testing of patient samples will be conducted by more than one operator, and the testing will be equally distributed among the operators at each site. The 3 New Zealand (NZ) sites will be classified as “untrained user” sites and will receive no formal training on the performance and interpretation of the investigational device. No additional written procedures beyond the information contained within the protocol and the written test procedure will be provided. The test operators at the “untrained user” sites will be provided with an operator questionnaire at the conclusion of enrollment at that site. All specimens will be tested with the Clearview (registered trademark) Influenza A+B Test according to product instructions, and will be sent to a clinical laboratory for viral culture

This study aims to evaluate the safety and efficacy of high dose vitamin D therapy in patients who have primary melanoma which has been treated and are at high risk of recurrence. Who is it for? You may be eligible to join this study if you aged 18 to 79 years and have been diagnosed with cutaneous melanoma. Study details: Participants in this study are randomly allocated (by chance) to one of two groups. Participants in one group will receive vitamin D3 tablets monthly for 24 months, whilst participants in the other group will receive a placebo (sugar pill). Participants will be followed-up for 24 months, in order to determine dose sufficiency, compliance, safety and progression free survival.

Restructuring maternity services to introduce caseload midwifery care involves radical changes to the organisation of conventional or routine midwifery and obstetric practices. All these changes make an impact on health planning and the allocation of finite resources. Many innovations are introduced in a relative policy vacuum. Models of maternity care are no exception. In addition to evidence on the experiences of women receiving caseload midwifery care and the experiences of obstetricians and midwives offering caseload care, the outcomes of the proposed trial will contribute: 1. Level 1 evidence of the safety and effectiveness of having a known caseload midwife for the continuum of pregnancy birth and postnatally. 2. Level 1 evidence of the safety and effectiveness of caseload midwifery care for women of all risk. 3. Level 1 evidence on the cost effectiveness of caseload midwifery care and routine obstetric care for all women. 4. ‘Australian randomised controlled trial data to the Cochrane systematic review of midwife led care.

To evaluate use of cognitive behavioural therapy to treat anxiety and depression in clients with Asperger's Disorder

The aim of this study is to determine if injecting corticosteroid into the knee during total knee replacement results in improved pain and function (in the short to medium term).

A melanoma-specific QoL questionnaire is being developed in a cross-cultural setting using a four phase process developed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. This study has shown that melanoma patients have important QoL issues that have been incorporated into a new cross-culturally validated instrument.

The primary aim of this trial is to compare the outcomes and adverse events of two different physiotherapy treatment approaches for people with reducible discogenic low back pain (with or without associated leg symptoms). A secondary aim is to determine the perspectives of participants on the specific physiotherapy treatment and advice utilised in the trial.

Adenosine has never been studied in coronary angioplasty in the setting of non ST segment elevation acute coronary syndrome. With promising observations of the benefits of adenosine in both elective and primary angioplasty settings, we hypothesise that intracoronary adenosine may prevent myocyte death (periprocedural myonecrosis) in this groups of patients undergoing coronary angioplasty. We hypothesise that pretreatment with a intracoronary bolus dose of adenosine before coronary angioplasty decreases the amount of periprocedural myonecrosis in patients with non ST segment elevation acute coronary syndrome

At present few methods of determining dietary intake in this group have been validated. The aim of the study is to evaluate the validity of two dietary assessment instruments (Cancer Council’s Food Frequency Questionnaire (FFQ) and duplicate 24h recall) against a reference technique (3-day weighted record) in a sample of community-dwelling older adults. This will potentially provide Dietitians (particularly researchers) with a simple, valid tool to assess dietary intake in this population

This study looks at the safety and effectiveness of using T cell therapy targeting Human Cytomegalovirus (HCMV) in treating brain cancer (glioblastoma multiforme or GBM). Who is it for? You can join this study if you have brain cancer (glioblastoma multiforme) that has progressed or recurred since it was first diagnosed. Trial details Participants will receive treatment with killer T cells (a type of white blood cell) which have been grown in the laboratory from the participant’s own white blood cells. Treatment is 4 fortnightly infusions, and patients are monitored for 12 months afterwards to see if treatment is safe and to measure any reduction in tumour and amount of virus in the blood. Recent studies suggest that most gliomas carry a common virus, called human cytomegalovirus (HCMV), which is normally controlled by killer T cells. The study aims to see if killer T cells grown in the laboratory and trained to recognise and kill the virus can also kill HCMV infected gliomas. The standard first-line treatment is usually surgery, radiotherapy and a chemotherapy drug called temozolomide. If the cancer then grows back, there are no known effective treatments.